Literature DB >> 32983146

Immunoregulatory Roles of Extracellular Vesicles and Associated Therapeutic Applications in Lung Cancer.

Zhengrong Yin1, Jinshuo Fan1, Juanjuan Xu1, Feng Wu1, Yang Li1, Mei Zhou1, Tingting Liao1, Limin Duan1, Sufei Wang1, Wei Geng1, Yang Jin1.   

Abstract

Lung cancer represents a fatal condition that has the highest morbidity and mortality among malignancies. The currently available treatments fall short of improving the survival and quality of life of late-stage lung cancer patients. Extracellular vesicles (EVs) secreted by tumors or immune cells transport proteins, lipids, and nucleic acids to other cells, thereby mediating immune regulation in the tumor microenvironment. The cargo carried by EVs vary by cellular state or extracellular milieu. So far, multiple studies have suggested that EVs from lung tumor cells (TEVs) or immune cells promote tumor progression mainly through suppressing antitumor immunity. However, modified or engineered EVs can be used as vaccines to elicit antitumor immunity. In addition, blocking the function of immunosuppressive EVs and using EVs carrying immunogenic medicine or EVs from certain immune cells also shows great potential in lung cancer treatment. To provide information for future studies on the role of EVs in lung cancer immunity, this review focus on the immunoregulatory role of EVs and associated treatment applications in lung cancer.
Copyright © 2020 Yin, Fan, Xu, Wu, Li, Zhou, Liao, Duan, Wang, Geng and Jin.

Entities:  

Keywords:  extracellular vesicles; immunostimulation; immunosuppression; lung cancer; therapeutic application

Mesh:

Substances:

Year:  2020        PMID: 32983146      PMCID: PMC7483575          DOI: 10.3389/fimmu.2020.02024

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  106 in total

1.  Cell-specific uptake of mantle cell lymphoma-derived exosomes by malignant and non-malignant B-lymphocytes.

Authors:  Inbal Hazan-Halevy; Daniel Rosenblum; Shiri Weinstein; Osnat Bairey; Pia Raanani; Dan Peer
Journal:  Cancer Lett       Date:  2015-04-28       Impact factor: 8.679

Review 2.  Regulation of immune responses by extracellular vesicles.

Authors:  Paul D Robbins; Adrian E Morelli
Journal:  Nat Rev Immunol       Date:  2014-03       Impact factor: 53.106

3.  Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide Aptamer.

Authors:  Jessica Gobbo; Guillaume Marcion; Marine Cordonnier; Alexandre M M Dias; Nicolas Pernet; Arlette Hammann; Sarah Richaud; Hajare Mjahed; Nicolas Isambert; Victor Clausse; Cédric Rébé; Aurélie Bertaut; Vincent Goussot; Frédéric Lirussi; François Ghiringhelli; Aurélie de Thonel; Pierre Fumoleau; Renaud Seigneuric; Carmen Garrido
Journal:  J Natl Cancer Inst       Date:  2015-11-22       Impact factor: 13.506

4.  Tumor cell-derived microparticles polarize M2 tumor-associated macrophages for tumor progression.

Authors:  Ruihua Ma; Tiantian Ji; Degao Chen; Wenqian Dong; Huafeng Zhang; Xiaonan Yin; Jingwei Ma; Xiaoyu Liang; Yi Zhang; Guanxin Shen; Xiaofeng Qin; Bo Huang
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

Review 5.  Dendritic cell-derived exosomes for cancer therapy.

Authors:  Jonathan M Pitt; Fabrice André; Sebastian Amigorena; Jean-Charles Soria; Alexander Eggermont; Guido Kroemer; Laurence Zitvogel
Journal:  J Clin Invest       Date:  2016-04-01       Impact factor: 14.808

6.  Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression.

Authors:  Angélique Bobrie; Sophie Krumeich; Fabien Reyal; Chiara Recchi; Luis F Moita; Miguel C Seabra; Matias Ostrowski; Clotilde Théry
Journal:  Cancer Res       Date:  2012-08-03       Impact factor: 12.701

7.  Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment.

Authors:  M Garofalo; H Saari; P Somersalo; D Crescenti; L Kuryk; L Aksela; C Capasso; M Madetoja; K Koskinen; T Oksanen; A Mäkitie; M Jalasvuori; V Cerullo; P Ciana; M Yliperttula
Journal:  J Control Release       Date:  2018-06-01       Impact factor: 9.776

8.  Transforming growth factor beta induces fibroblasts to express and release the immunomodulatory protein PD-L1 into extracellular vesicles.

Authors:  Jeong-Han Kang; Mi-Yeon Jung; Malay Choudhury; Edward B Leof
Journal:  FASEB J       Date:  2019-12-12       Impact factor: 5.191

9.  Activated T cell exosomes promote tumor invasion via Fas signaling pathway.

Authors:  Zhijian Cai; Fei Yang; Lei Yu; Zhou Yu; Lingling Jiang; Qingqing Wang; Yunshan Yang; Lie Wang; Xuetao Cao; Jianli Wang
Journal:  J Immunol       Date:  2012-05-09       Impact factor: 5.422

Review 10.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

View more
  9 in total

1.  In Situ Deployment of Engineered Extracellular Vesicles into the Tumor Niche via Myeloid-Derived Suppressor Cells.

Authors:  Silvia Duarte-Sanmiguel; Ana Panic; Daniel J Dodd; Ana Salazar-Puerta; Jordan T Moore; William R Lawrence; Kylie Nairon; Carlie Francis; Natalie Zachariah; William McCoy; Rithvik Turaga; Aleksander Skardal; William E Carson; Natalia Higuita-Castro; Daniel Gallego-Perez
Journal:  Adv Healthc Mater       Date:  2021-10-27       Impact factor: 9.933

2.  A systematic review of extracellular vesicles as non-invasive biomarkers in glioma diagnosis, prognosis, and treatment response monitoring.

Authors:  Arman Sourani; Saeid Saghaei; Masih Sabouri; Masoud Soleimani; Leila Dehghani
Journal:  Mol Biol Rep       Date:  2021-08-30       Impact factor: 2.316

Review 3.  Synergies of Extracellular Vesicles and Microchimerism in Promoting Immunotolerance During Pregnancy.

Authors:  José M Murrieta-Coxca; Paulina Fuentes-Zacarias; Stephanie Ospina-Prieto; Udo R Markert; Diana M Morales-Prieto
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

Review 4.  Cancer Stem Cells (CSCs), Circulating Tumor Cells (CTCs) and Their Interplay with Cancer Associated Fibroblasts (CAFs): A New World of Targets and Treatments.

Authors:  Beatrice Aramini; Valentina Masciale; Chiara Arienti; Massimo Dominici; Franco Stella; Giovanni Martinelli; Francesco Fabbri
Journal:  Cancers (Basel)       Date:  2022-05-13       Impact factor: 6.575

Review 5.  Commensal and Pathogenic Bacterial-Derived Extracellular Vesicles in Host-Bacterial and Interbacterial Dialogues: Two Sides of the Same Coin.

Authors:  Samira Tarashi; Mohammad Saber Zamani; Mir Davood Omrani; Abolfazl Fateh; Arfa Moshiri; Ahmad Saedisomeolia; Seyed Davar Siadat; Stan Kubow
Journal:  J Immunol Res       Date:  2022-02-17       Impact factor: 4.818

Review 6.  Tumor-derived extracellular vesicles as messengers of natural products in cancer treatment.

Authors:  Yuanxin Xu; Kuanhan Feng; Huacong Zhao; Liuqing Di; Lei Wang; Ruoning Wang
Journal:  Theranostics       Date:  2022-01-16       Impact factor: 11.556

Review 7.  Extracellular Vesicles and Interleukins: Novel Frontiers in Diagnostic and Therapeutic for Cancer.

Authors:  Aline G Souza; Leandro M Colli
Journal:  Front Immunol       Date:  2022-03-21       Impact factor: 7.561

8.  Extracellular Vesicle Transportation and Uptake by Recipient Cells: A Critical Process to Regulate Human Diseases.

Authors:  Zhi Hao Kwok; Chenghao Wang; Yang Jin
Journal:  Processes (Basel)       Date:  2021-01-31       Impact factor: 2.847

9.  MicroRNA-449a delays lung cancer development through inhibiting KDM3A/HIF-1α axis.

Authors:  Shan Hu; Peng Cao; Kangle Kong; Peng Han; Yu Deng; Fan Li; Bo Zhao
Journal:  J Transl Med       Date:  2021-05-27       Impact factor: 5.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.